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E¡ect of oxolamine on cough sensitivity in COPD
patients
B.B.CEYHAN AND S.KARAKURT
Department of Pulmonary Medicine,Marmara University School of Medicine, Istanbul,TurkeyCough is the most common symptom of chronic
obstructive pulmonary disease (COPD) (1). Mucolytic
expectorant and anti-tussive therapy had been largely
overlooked because of the di⁄culty in demonstrating
e¡ectiveness by objective criteria, the lack of de¢nitive
clinical data and uncertainty about the type of patients
who are likely to bene¢t from this therapeutic modality.
Oxolamine is one of the synthetic derivatives of 3,5-
disubstituted 1,2,4-oxodiazole, used particularly for its
anti-tussive activity (2). Although the anti-in£ammatory
action of oxolamine in the airway was observedin animal
experiments, little is known about the e¡ect of oxola-
mine on the cough symptoms of COPD patients (3).
The provocation studies would be useful in studies of
cough.Capsaicin is thepurgentcomponentof hotpepper
that speci¢cally stimulates a¡erent nerve ¢bres,
non-myelinated C-¢bre endings in the lungs (4). It is well
tolerated as a coughprovocator inCOPDpatients (5^7).
The primary objective of this study was to assess the
safety and e⁄cacy of orally administered oxolamine
syrupp vs. placebo as an adjunctive therapy and to
evaluate objectively the use of cough sensitivity test in
determining the e⁄cacy of anti-tussive therapy in
patients with COPD.
This study was carried out on19 COPD patients with
the symptom of cough as de¢ned by ATS criteria (l). Pa-
tients completed a cough and other symptoms diary dur-
ing an initial1week run-in period. Symptom parameters
included assessments of the following: cough frequency,
sputumproduction, chest discomfort, dyspnoea and fre-
quency of as-required b2 agonist use.The patients’global
assessment was de¢ned as the sum of symptom scores
which contained a de¢nition of each rating scale (1^5)
(8). At the end of the run-in period, cough sensitivity toReceived 27 September 2000, accepted in revised form16 August 2001
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measured.The patients were then randomized to either
oral oxolamine phosphate syrup (PEREBRONs 50mg
5mlÿ1, Santa Pharma, Istanbul, Turkey) or placebo (pre-
pared by drug company). Four weeks later they had re-
peated cough challengewith capsaicin, lung function test
and 1week symptom scoring. The same procedure was
then repeated with the other choice. Each patient
received 100mg oxolamine twice daily. The assigned
regimen was entered to each patient for 4 weeks in a
single-blind,
placebo-controlled, cross-over, randomized design.
Measurement of cough threshold to inhaled capsaicin
was carried out using the method reported previously
(9). The capsaicin cough threshold was de¢ned as the
lowest concentration of capsaicin causing ¢ve or more
coughs (D5).Capsaicin cough threshold values were log-
transformed and expressed as geometric mean 7SEM.
Friedman variance analysis, Wilcoxon-signed rank test
and Spearman Rank correlation tests were used as sta-
tistical tests.
The clinical characteristics of patients are given in
Table1.Regardingpulmonary function tests no signi¢cant
changeswere observedin each studyperiod (Table1).Ten
of 19 (53%) of patients reported improvement and relief
of cough symptoms after oxolaminebut symptom scores
did not result in any statistical signi¢cance. The geo-
metric mean of cough threshold was ÿ0?2370?03mM
(95% CI:ÿ0?30 to ÿ0?17) in run-in period and ÿ0?10
70?07mM (95% CI:ÿ0?26^0?05) after placebo, and 0?16
70?09mM (95% CI:ÿ0?040^0?36) after oxolamine
(Po0?01, Table 1). The capsaicin cough threshold
increased signi¢cantly after oxolamine compared with
the run-in period (Po0?0007); there was no signi¢cant
di¡erence between placebo and run-in period cough
thresholds (Table 1). The cough threshold for capsaicin
increased in 6/19 (32%) of patients after placebo and in
12/19 (63%) of patients after oxolamine. There were no
correlations between cough threshold and lung function
test parameters and symptom scores.




Duration of disease (yr) 9?679?0
Run-inperiod Placebo Oxolamine
FEV1 (l) 1?4670?79 1?5570?86 1?5370?88
FEV1pred (%) 52?8721?9 54?6724?2 55?5724?8
FEv1/FVC (%) 60?6713?2 62?0714?3 60?0715?8
Symptoms cores 2?0270?69 1?9170?74 1?9270?76
Cough score 2?1470?98 2?0170?99 1?9671?08
Cough sensitivity
(D5 log) mM ÿ0?2370?03 ÿ0?1070?07 0?1670?09*
CI95% ÿ0?30^0?17 ÿ0?26^0?05 ÿ0?040^0?36
*Po0?01.
62 RESPIRATORYMEDICINEThe reasons for the di¡erence between perception
and cough sensitivity are unclear. It is known that the
patients with more severe ¢xed airway obstruction
perceive acute changes in dyspnoea less well and dys-
pnoea is poorly correlatedwith lung function test indices
(10). Furthermore, the perception of symptoms for
COPD patients is known to be blunted in comparison
with normal controls and asthmatics (11). Hence, they
may not register improvements in symptoms following
oxolamine therapy.
Ours is the ¢rst study to our knowledge to assess the
anti-tussive e¡ect of oxolamine in patients with COPD
using capsaicin test. A few studies with capsaicin were
appliedinpatientswithCOPDpreviously (5,7). Capsaicin
was used to investigate the e⁄cacy of several antitussive
drugs. Gamma-aminobutryic acid (GABA) is a central
inhibitory neurotransmitter that also exists in lung, has
been shown to inhibit cough response to inhaled capsai-
cin (12). Furthermore, Fuller et al. used capsaicin to
investigate the sensitivity of cough response against to
inhaled and systemic opiates (13).
We could not ¢nd any di¡erence in lung function test
parameters after oxolamine and any correlation bet-
ween forced expiratory volume in1sec (FEV1) and cough
symptom scores in our study. The ¢ndings of this study
were in agreement with previous reports in that no
signi¢cant changes in lung function parameters were
detected after adjunctive anti-tussive ormucolytic ther-
apy (14). It has also been shown that cough sensitivity did
not correlatewith FEV1in asthmatics (15).
In conclusion, this randomized single-blind, placebo-
controlled study demonstrated that oxolamine reduced
cough sensitivity and statistically insigni¢cant symptom
improvement in patients with COPD. These results
can be interpreted as a pilot observation rather than a
de¢nitive investigation because of small numbers of
patients and single-blind study protocol. Further studiesare needed to test clinical e¡ectiveness and safety of
oxolamine given as adjunctive therapy in COPDpatients.
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